Translational Research in Maternal and Pediatric Pharmacology and Therapeutics (R01 Clinical Trial Optional)
NIH funds translational and clinical research to improve safe and effective drug use, precision therapeutics, and medication development for pregnant and lactating women, fetuses, neonates, and children.
⚑ Clinical Trial Optional · No stated award ceiling · Includes foreign organizations and several minority-serving/tribal/faith-based/community-based eligible applicants
Unit fits — one characterization, each unit's own rules
| Physical Sciences & Engineering (demo) | 70 strong | technical depth: substantial; funds applied research |
| IPPRA | 58 good | portfolio topic: public_health; social/behavioral work is minor; funds applied research; clinical-trial/biomedical core — IPPRA angle is policy/community (capped) |
| Tom Love Innovation Hub | 30 weak | funds applied research; deep-tech content |
Description
The purpose of this notice of funding opportunity (NOFO) is to support translational and clinical research to (1) advance precision medicine in pregnant women, lactating women, and children through the development of novel tools, models, and other technologies that could have a direct clinical or health impact; (2) enhance the understanding of the underlying mechanisms of drug action, including the role of pediatric ontogeny and the dynamic physiological changes that occur during pregnancy and lactation; and (3) discover and develop novel therapeutics or enhance the usage of existing drugs or drug repurposing for safer and more effective medications in pregnant and lactating women, neonates, and children. The overall goal is to improve safe and effective precision therapeutics for pregnant and lactating women, fetuses, neonates, and children, including those with disabilities.
Eligibility
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
Apply
View on Grants.gov → CONTACT: National Institutes of Health <grantsinfo@nih.gov>
Proposal brief
Proposal shell · National Institutes of Health conventions
Legacy IPPRA LLM assessment (v2.0, for comparison)
35/100 · gpt-5.4-mini · 2026-07-06
This is clearly in public health and clinical therapeutics, but it is primarily translational/clinical biomedical research on drug safety and efficacy rather than the behavioral, communication, policy, or community-facing research that IPPRA typically anchors. A public university can apply, so eligibility is not a barrier, but the opportunity is only tangentially aligned with IPPRA’s core social-science and policy strengths.
Legacy scoring history
| 2026-07-06 | 35 | gpt-5.4-mini | This is clearly in public health and clinical therapeutics, but it is primarily translational/clinical biomedical research on drug safety and efficacy rather than the behavioral, communication, policy, or community-facing research that IPPRA typically anchors. A public university can apply, so eligibility is not a barrier, but the opportunity is only tangentially aligned with IPPRA’s core social-science and policy strengths. |
| 2026-07-06 | 23 | gpt-5.4-mini | This is a biomedical translational research opportunity focused on maternal, fetal, neonatal, and pediatric therapeutics. IPPRA’s strongest fit is limited to the health-communication, behavioral, or program-evaluation side of improving medication use or care engagement, but the NOFO is predominantly clinical/pharmacological rather than social-science driven. Public universities are eligible, so there is no eligibility cap, but overall the relevance to IPPRA is weak-tangential. |